- 2 - 5968-01-SMH

LISTING OF THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-5 (cancelled)

Claim 6 (previously presented) A method for treating arthritis comprising administering to a patient suffering from arthritis an effective antiarthritic amount of a MEK inhibitor, wherein the MEK inhibitor is a compound of Formula I

$$R_1$$
 R_2
 R_3
 R_4
 R_5
 R_5

wherein:

 R_1 is hydrogen, hydroxy, C_1 - C_8 alkyl, C_1 - C_8 alkoxy, halo, trifluoromethyl, or CN; R_2 is hydrogen;

R₃, R₄, and R₅ independently are hydrogen, hydroxy, halo, trifluoromethyl, C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, CN, or -(O or NH)_m-(CH₂)_n-R₉, where R₉ is hydrogen, hydroxy, COOH, or NR₁₀R₁₁;

n is 0-4:

m is 0 or 1;

R₁₀ and R₁₁ independently are hydrogen or C₁-C₈ alkyl, or taken together with the nitrogen to which they are attached can complete a 3-10 member cyclic ring optionally containing 1, 2, or 3 additional heteroatoms selected from O, S, NH, or N-C₁-C₈ alkyl;

Z is COOR₇, tetrazolyl, CONR₆R₇, CONHNR₁₀R₁₁, or CH₂OR₇;

R₆ and R₇ independently are hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, (CO)-C₁-C₈ alkyl, aryl, heteroaryl, or C₃-C₁₀ cycloalkyl optionally containing one, two, or three heteroatoms selected from O, S, NH, or N

5968-01-SMH

alkyl; or R₆ and R₇ together with the nitrogen to which they are attached complete a 3-10 member cyclic ring optionally containing 1,2, or 3 additional heteroatoms selected from O, S, NH, or N alkyl; and wherein any of the foregoing alkyl, alkenyl, aryl, heterocyclic, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, C₁-C₆ alkoxy, amino, nitro, C₁-C₄ alkylamino, di(C₁-C₄) alkylamino, C₃-C₆ cycloalkyl, phenyl, phenoxy, C₃-C₅ heteroaryl, or C₃-C₅ heteroaryloxy;

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 7 (previously presented) The method according to Claim 6 wherein the MEK inhibitor is a compound selected from:

[4-Chloro-2-(1H-tetrazol-5-yl)-phenyl-(4-iodo-2-methyl-phenyl)-amine;

(4-iodo-2-methyl-phenyl)-[2-(1H-tetrazol-5-yl)-phenyl]amine;

[4-nitro-2-(1H-tetrazol-5-yl)-phenyl-(4-iodo-2-methyl-phenyl)-amine;

4-Fluoro-2-(4-iodo-2-methylphenylamino)benzoic acid;

3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

Sodium 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoate;

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2-(4-Iodo-2-methyl-phenylamino)-5-nitro-benzoic acid;

4-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2-(4-Iodo-2-methyl-phenylamino)-benzoic acid;

5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

5-Iodo-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2,3,5-Trifluoro-4-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2-(4-Iodo-phenylamino)-5-methoxy-benzoic acid;

5-Methyl-2-(4-iodo-2-methyl-phenylamino)-benzoic acid;

2-(4-Iodo-2-methyl-phenylamino)-4-nitro-benzoic acid;

2-(4-Bromo-2-methyl-phenylamino)-4-fluoro-benzoic acid;

5968-01-SMH

- 2-(2-Bromo-4-iodo-phenylamino)-5-nitro-benzoic acid;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-benzoic acid;
- 5-Chloro-N-(2-hydroxyethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-benzamide;
- N-Ethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1H-tetrazol-5-yl)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
- [5-Chloro-2-(4-iodo-2-methyl-phenylamino)-benzoylamino]-acetic acid;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-propyl-benzamide;
- 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N.N-Diethyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N.N-Diethyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- N-Butyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N,N-diethyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N,N-dimethyl-benzamide;
- 5-Bromo-3,4-difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(2,3-Dihydroxy-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)benzamide:
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 3,4-Difluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(2,3-Dihydroxy-propyl)-4-fluoro-2-(4-iodo-2-methyl-phenylamino)benzamide:
- 3,4-Difluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;

- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
- 4-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-(3-dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
- N-(3-Dimethylamino-propyl)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Benzyl-4-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-hydroxy-ethyl)benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thiophen-2-yl-ethyl)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;

- 5968-01-SMH
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethylbenzamide:
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-N-(3-dimethylamino-propyl)-3,4-difluorobenzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyridin-4-yl-ethyl)-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(3-hydroxy-propyl)benzamide:
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenethyl-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-thiophen-2-yl-ethyl)-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-pyridin-4-ylmethylbenzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-phenethyl-benzamide;
- 2-(4-Bromo-2-methyl-phenylamino)-3,4-difluoro-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 5-Chloro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- 5-Fluoro-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-pyridin-4-yl methyl-benzamide;
- 5-Bromo-N-{3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide;

- 5-Chloro-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)benzamide:
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)benzamide;
- (3-Hydroxy-pyrrolidin-1-yl)-[2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanone:
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 5-Bromo-N-(2-diethylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)benzamide;
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-chloro-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-bromo-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- N-{3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-propyl}-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-pyridin-4-ylmethyl-benzamide;
- 5-Bromo-2-(4-iodo-2-ethyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide:
- 5-Chloro-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide:
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-(3-diethylamino-2-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperidin-1-yl-ethyl)-benzamide:

- 5968-01-SMH
- 5-Bromo-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)benzamide;
- N-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethyl}-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 5-Chloro-N-(3-diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)benzamide;
- 5-Chloro-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide:
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(2-piperidin-1-yl-ethyl)-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-piperazin-1-yl-ethyl)-benzamide;
- N-(2-Diethylamino-ethyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-(3-dimethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(3-Hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 5-Fluoro-N-(3-hydroxy-propyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(3-Diethylamino-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)benzamide;
- N-(3-Diethylamino-propyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(3-piperidin-1-yl-propyl)benzamide;
- [5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-(3-hydroxy-pyrrolidin-1-yl)-methanone;

5968-01-SMH ·

- 5-Bromo-N-(2-diisopropylamino-ethyl)-2-(4-iodo-2-methyl-phenylamino)benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide:
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-piperidin-1-yl-propyl)-benzamide;
- [5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone;
- N-(3-Diethylamino-2-hydroxy-propyl)-5-fluoro-2-(4-iodo-2-methyl-phenylamino)- benzamide;
- N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-(2-Hydroxy-ethyl)-2-(4-iodo-2-ethyl-phenylamino)-5-nitro-benzamide;
- 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide;
- 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
- N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;
- N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;
- N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide;
- N-Cyclopropyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide; N-Benzyloxy-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide; N-Cyclohexyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Allyl-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide; 2-(4-Iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-5-nitro-benzamide; 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide; N-Cyclohexyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Chloro-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide; 5-Bromo-N-cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-benzyl)-benzamide; N-Cyclohexyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide; N-Benzyloxy-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Benzyloxy-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Chloro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Bromo-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide; 2-(4-Iodo-2-methyl-phenylamino)-N-methyl-5-nitro-N-phenyl-benzamide; 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide; N-(2-Hydroxy-ethyl)-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Chloro-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Allyl-5-chloro-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide; N-(2-Hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide; 5-Fluoro-N-(2-hydroxy-ethyl)-2-(4-iodo-2-methyl-phenylamino)-benzamide; 5-Bromo-N-cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Cyclopropyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Cyclopropyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide; N-Allyl-5-fluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide; N-Benzyloxy-5-iodo-2-(4-iodo-2-methyl-phenylamino)-benzamide;

N-Allyl-5-bromo-2-(4-iodo-2-methyl-phenylamino)-benzamide;

09/868,120 - 11 - 5968-01-SMH

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-methyl-N-phenyl-benzamide;

N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-benzyl alcohol;

[5-Chloro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol;

[2-(4-Iodo-2-methyl-phenylamino)-5-nitro-phenyl]-methanol;

[5-Bromo-2-(4-iodo-2-methyl-phenylamino)-phenyl]-methanol; and

N-Allyl-2-(4-iodo-2-methyl-phenylamino)-5-nitro-benzamide;

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 8 (previously presented) The method of claim 6, wherein the MEK inhibitor is a compound of Formula (I) wherein (a) R₁ is hydrogen, methyl, methoxy, fluoro, chloro, or bromo; (b) R₂ is hydrogen; (c) R₃, R₄, and R₅ independently are hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, or nitro; (d) R₁₀ and R₁₁ independently are hydrogen or methyl; (e) Z is COOR₇, tetrazolyl, CONR₆R₇, CONHNR₁₀R₁₁, or CH₂OR₇; R₆ and R₇ independently are hydrogen, C ₁₋₄ alkyl, heteroaryl, or C ₃₋₅ cycloalkyl optionally containing one or two heteroatoms selected from O, S, or NH; or R₆ and R₇ together with the nitrogen to which they are attached complete a 5-6 member cyclic ring optionally containing 1 or 2 additional heteroatoms selected from O, NH or N-alkyl; and wherein any of the foregoing alkyl or aryl groups can be unsubstituted or substituted by halo, hydroxy, methoxy, ethoxy, or heteroaryloxy.

Claim 9 (original) The method of claim 8, wherein the MEK inhibitor is a compound of Formula (I) wherein: Z is COOR₇; R_7 is H, pentafluorophenyl, or tetrazolyl; R_3 and R_5 are independently H, fluoro, or chloro; and R_4 is fluoro.

Claim 10 (previously presented) A method for treating arthritis comprising administering to a patient suffering from arthritis an effective antiarthritic amount of a MEK inhibitor, wherein the MEK inhibitor is a compound of Formula II

5968-01-SMH

$$R_{1a}$$
 R_{2a}
 $C-N-O-R_{7a}$
 R_{3a}
 R_{4a}

wherein:

R_{1a} is hydrogen, hydroxy, C₁-C₈ alkyl, C₁-C₈ alkoxy, halo, trifluoromethyl, or CN;

R_{2a} is hydrogen;

R_{3a}, R_{4a}, and R_{5a} independently are hydrogen, hydroxy, halo, trifluoromethyl,

C₁-C₈ alkyl, C₁-C₈ alkoxy, nitro, CN, or (O or NH)_m-(CH₂)_n-R_{9a}, where

R_{9a} is hydrogen, hydroxy, CO₂H or NR_{10a}R_{11a}.

n is 0-4:

m is 0 or 1;

R_{10a} and R_{11a} independently are hydrogen or C₁-C₈ alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N-C₁-C₈ alkyl;

R_{6a} is hydrogen, C₁-C₈ alkyl, (CO)-C₁-C₈ alkyl, aryl, aralkyl, or C₃-C₁₀ cycloalkyl;

R_{7a} is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,

C₃-C₁₀ (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or NR_{9a});

and wherein any of the foregoing alkyl, alkenyl, aryl, heteroaryl, heterocyclic, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, C₁-C₆ alkoxy, amino, nitro, C₁-C₄ alkylamino, di(C₁-C₄)alkylamino, C₃-C₆ cycloalkyl, phenyl, phenoxy, C₃-C₅ heteroaryl or heterocyclic radical, or C₃-C₅ heteroaryloxy or heterocyclic radical-oxy; or R_{6a} and R_{7a} taken

5968-01-SMH

together with the N to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or NR_{10a}R_{11a};

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.

Claim 11 (original) The method of Claim 10, comprising a MEK inhibitor having a structure of Formula (II) wherein: (a) R_{1a} is H, methyl, fluoro, or chloro; (b) R_{2a} is H; R_{3a} , R_{4a} , and R_{5a} are each H, Cl, nitro, or F; (c) R_{6a} is H; (d) R_{7a} is methyl, ethyl, 2-propenyl, propyl, butyl, pentyl, hexyl, cyclopropylmethyl, cyclobutyl methyl, cyclopropylmethyl, or cyclopropylethyl; and (e) the 4' position is I, rather than Br.

Claim 12 (original) The method of claim 11, comprising a MEK inhibitor having a structure of Formula (II) wherein: R_{4a} is F at the 4 position, para to the CO-N- R_{6a} -OR_{7a} group and meta to the bridging nitrogen; at least one of R_{3a} and R_{5a} is F or Cl; and R_{1a} is methyl or chloro.

Claim 13 (previously presented) The method of Claim 10, comprising a MEK inhibitor having a formula selected from:

- 4-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(methoxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-enyloxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentoxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-ethoxy-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)benzamide;

- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(1-methylprop-2-ynyloxy)-benzamide:
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-5-phenylpent-2-en-4-ynyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide;
- 3.4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(propoxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclobutyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-methyl-prop-2-enyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide;
- 3.4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopentyloxy)-benzamide;
- 3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynyloxy)-benzamide;
- 5-Bromo-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide:
- 5-Bromo-3,4-difluoro-N-(furan-3-ylmethoxy)-2-(4-iodo-2-methyl-phenylamino)-benzamide:
- 5-Bromo-N-(but-2-enyloxy)-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide
- 5-Bromo-N-butoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-but-2-enyloxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-methyl-pent-2-en-4-ynyloxy)-benzamide;

- 5968-01-SMH
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-benzyl)-N-[5-(3-methoxy-phenyl)-3-methyl-pent-2-en-4-ynyloxy]-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(prop-2-ynyloxy)-benzamide:
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-[3-(3-methoxy-phenyl)-prop-2-ynyloxy]-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(thiopen-2-ylmethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(pyridin-3-ylmethoxy)-benzamide;
- 5-Bromo-3-4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(3-(2-fluorophenyl)-prop-2-ynyloxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(ethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)-benzamide;
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide:
- 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-but-3-ynyloxy)-benzamide:
- 5-Chloro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydro-pyran-2-yloxy)-benzamide:
- 5-Chloro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide;
- 4-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;
- 4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;
- 5-Fluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-phenylmethoxy-benzamide;
- 5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(tetrahydropyran-2-yloxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-phenylprop-2-ynyloxy)-benzamide:

- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-furylmethoxy)-benzamide:
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-thienylmethoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-3-ynyloxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-methyl-prop-2-enyloxy)- benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(but-2-enyloxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(methoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(ethoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclobutoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(isopropoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(2-phenoxyethoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopropylmethoxy)benzamide:
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(n-propoxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(1-methyl-prop-2-ynyloxy)-benzamide:
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(3-(3-fluorophenyl)-prop-2-ynyloxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(4,4-dimethylpent-2-ynyloxy)-benzamide;
- 3,4-Difluoro-2-(4-bromo-2-methyl-phenylamino)-N-(cyclopentoxy)-benzamide;
- 3,4,5-Trifluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Chloro-3,4-difluoro-N-hydroxy-2-(4-iodo-2-methyl-phenylamino)-benzamide;
- 5-Bromo-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- N-Hydroxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;
- 3,4,5-Trifluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;

- 2-(2-Fluoro-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
- 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-hydroxy-4-methyl-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-3,4,5-trifluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-5-chloro-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-N-hydroxy-4-nitro-benzamide;
- 4-Fluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-4-fluoro-N-hydroxy-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-3,4-difluoro-N-hydroxy-benzamide;
- N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide:
- 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide:
- 5-Bromo-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)benzamide;
- N-Cyclopropylmethoxy-2-(4-iodo-2-methyl-phenylamino)-4-nitro-benzamide;
- N-Cyclopropylmethoxy-3,4,5-trifluoro-2-(2-fluoro-4-iodo-phenylamino)benzamide;
- 5-Chloro-N-cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)benzamide;
- 5-Bromo-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide;
- N-Cyclopropylmethoxy-2-(2-fluoro-4-iodo-phenylamino)-4-nitro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;

- 5968-01-SMH
- 5-Chloro-2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide;
- 5-Bromo-2-(2-bromo-4-iodo-phenylamino)-N-ethoxy-3,4-difluoro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-ethoxy-4-nitro-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4,5-trifluoro-benzamide;
- 2-(2-Bromo-4-iodo-phenylamino)-5-chloro-N-cyclopropylmethoxy-3,4-difluorobenzamide
- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-nitro-benzamide;
- N-Cyclopropylmethoxy-4-fluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide;
- N-Cyclopropylmethoxy-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide;
- 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide:
- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-4-fluoro-benzamide; and
- 2-(2-Bromo-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide;

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 14 (previously presented) The method of claim 1, comprising a MEK inhibitor having a structure selected from:

- 2-(2-chloro-4-iodophenylamino)-5-chloro-N-cyclopropylmethoxy -3,4-difluorobenzamide:
- 2-(4-iodophenylamino)-N-cyclopropylmethoxy-5-chloro-3,4-difluorobenzamide;
- 2-(4-iodophenylamino)-5-chloro-3,4-difluorobenzoic acid:
- 2-(2-chloro-4-iodophenylamino)-5-chloro-3,4-difluorobenzoic acid;
- 5-chloro-3,4-difluoro-2-(4-iodo-2-methylphenylamino)-benzoic acid; and
- 5-chloro-N-cyclopropylmethoxy -3,4-difluoro-2-(4-iodo-2-methylphenylamino)-benzamide;

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 15 (previously presented) A method of treating arthritis in a patient in need of treatment, or suspected of developing arthritis, said method comprising the step of administering an effective antiarthritic amount of a compound selected from:

- 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-hydroxy-3,4-difluoro-5-bromobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-cyclobutylmethoxy-3,4-difluoro-5-bromobenzamide;
- 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide;
- 2-(2-Chloro-4-iodophenylamino)-N-hydroxy-3,4-difluoro-5-bromobenzamide;
- 2-(2-Chloro-4-iodophenylamino)-N-cyclobutylmethoxy-3,4-difluorobenzamide;
- 2-(2-Chloro-4-iodophenylamino)-N-hydroxy-4-fluorobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-hydroxy-3,4-difluorobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-cyclopropylmethoxy-
 - 3,4,5-trifluorobenzamide; and
- 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-4-fluorobenzamide; or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 16 (previously presented) The method of Claim 15 wherein said compound is selected from

- 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide;
- 2-(2-Methyl-4-iodophenylamino)-N-cyclopropylmethoxy-
 - 3,4,5-trifluorobenzamide; and
- 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-4-fluorobenzamide; or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 17 (previously presented) A method of treating or reducing the risk of arthritis in a patient in need of treatment, or suspected of developing arthritis, said method comprising the step of administering an effective antiarthritic amount of 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, or a pharmaceutically acceptable salt thereof.

~ 20 -

Claim 18 (previously presented) The method of Claim 8, wherein the MEK inhibitor is a compound of Formula (I) wherein: Z is $COOR_7$; R_7 is H, pentafluorophenyl, or tetrazolyl; and R_3 , R_4 , and R_5 are independently H, fluoro, or chloro.

Claim 19 (previously presented) The method of Claim 8, wherein the MEK inhibitor is a compound of Formula (I) wherein: Z is COOR₇; R₇ is H, pentafluorophenyl, or tetrazolyl; and R₃, R₄, and R₅ independently are fluoro.

Claim 20 (previously presented) A method for treating rheumatoid arthritis comprising administering to a patient suffering from rheumatoid arthritis a therapeutically effective amount of 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, or a pharmaceutically acceptable salt thereof.

Claim 21 (previously presented) A method for treating osteoarthritis comprising administering to a patient suffering from osteoarthritis a therapeutically effective amount of 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, or a pharmaceutically acceptable salt thereof.

Claim 22 (previously presented) The method for treating arthritis of Claim 6 wherein the arthritis is rheumatoid arthritis.

Claim 23 (previously presented) The method for treating arthritis of Claim 6 wherein the arthritis is osteoarthritis.

Claim 24 (previously presented) A method for treating arthritis, the method comprising administering to a patient suffering from arthritis an effective antiarthritic amount of a MEK inhibitor, wherein the MEK inhibitor is a compound selected from:

2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide;

5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;

5-Iodo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide;

2-(4-Iodo-2-methyl-phenylamino)-5-nitro-N-(4-sulfamoyl-benzyl)-benzamide;

5-Fluoro-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide; and

5-Bromo-2-(4-iodo-2-methyl-phenylamino)-N-(4-sulfamoyl-benzyl)-benzamide; or

a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Claim 25 (previously presented) The method for treating arthritis according to claim 10, wherein R_{1a} is H, methyl, fluoro, or chloro; R_{6a} is H; the 4' position is L, rather than Br; R_{4a} is F at the 4 position, para to the CO-N- R_{6a} -OR_{7a} group and meta to the bridging nitrogen; and R_{3a} or R_{5a} is F.

Claim 26 (previously presented). The method for treating arthritis according to claim 25, wherein the MEK inhibitor is a compound of Formula II

$$\begin{array}{c|c} R_{1a} & C & R_{6a} \\ R_{1a} & C & N-O-R_{7a} \\ \hline \\ R_{3a} & R_{4a} \end{array}$$

wherein:

the 4' position is I, rather than Br;

R_{1a} H, methyl, fluoro, or chloro;

- 22 -

5968-01-SMH

R_{2a} is hydrogen;

 R_{3a} or R_{5a} is F and the other of R_{3a} or R_{5a} independently is hydrogen, hydroxy, halo, trifluoromethyl, C1-C8 alkyl, C1-C8 alkoxy, nitro, CN, or (O or NH)_m-(CH₂)_n-R_{9a}, where R_{9a} is hydrogen, hydroxy, CO₂H or NR_{10a}R_{11a}:

R_{4a} is F at the 4-position, para to the CO-N-R_{6a}-OR_{7a} group and meta to the bridging nitrogen;

n is 0-4:

m is 0 or 1;

R_{10a} and R_{11a} independently are hydrogen or C₁-C₈ alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N-C₁-C₈ alkyl;

R_{6a} is H;

R_{7a} is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₁₀ (cycloalkyl or cycloalkyl optionally containing a heteroatom selected from O, S, or NR9a);

and wherein any of the foregoing alkyl, alkenyl, aryl, heteroaryl, heterocyclic, and alkynyl groups can be unsubstituted or substituted by halo, hydroxy, C_1 - C_6 alkoxy, amino, nitro, C_1 - C_4 alkylamino, di(C_1 - C_4)alkylamino, C_3 - C_6 cycloalkyl, phenyl, phenoxy, C₃-C₅ heteroaryl or heterocyclic radical, or C₃-C₅ heteroaryloxy or heterocyclic radicaloxy; or R_{6a} and R_{7a} taken together with the N to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or NR_{10a}R_{11a}.

Claim 27 (previously presented) The method for treating arthritis according to claims 25 or 26, wherein the arthritis is rheumatoid arthritis.

- 23 -

5968-01-SMH

Claim 28 (previously presented) The method for treating arthritis according to claims 25 or 26, wherein the arthritis is osteoarthritis.